In 2027, drug developers who secure supply early will have a clear advantage. Capacity for complex molecules is tightening, which makes the right manufacturing partner harder to find. The biggest pressure comes from peptides, where demand is growing faster than new plants can open.
Small molecules add a second strain because they remain central to new drugs, even as their chemistry grows more complex. On top of both, the new US policy is turning a supplier's location into a compliance question. Together, these shifts push companies to plan earlier and commit to long-term partners. Those who wait until late development to find capacity risk costly delays to their schedules.
CDMO leaders expect demand for specialized capacity to stay ahead of supply in 2027. In their view, peptides will feel this squeeze first, and small molecules will follow close behind.
Saharsh Davuluri, CEO of Neuland Labs, has explained both pressures in recent interviews. His peptide outlook starts with GLP-1 drugs, which he says changed what manufacturers can deliver. At DCAT Week 2026, he noted that making peptides at metric-ton scale is "no longer challenging." With large-scale production now proven, he sees peptide demand spreading beyond obesity and diabetes.
CDMOs are therefore responding with major investments, committing billions of dollars to new peptide plants worldwide.
Small molecules face a different kind of strain. Many now involve more complex chemistry, which raises the skill level a partner needs. These projects often require specialized equipment and experienced process chemists. Taken together, both trends pull API and peptide outsourcing in one direction. Companies will plan earlier and build fewer, deeper partnerships with the CDMOs they trust.
GLP-1 drugs will keep large peptide plants heavily booked through 2027. As a result, other peptide projects will need to reserve manufacturing time much earlier than before.
The scale of patient uptake explains the pressure on API and peptide outsourcing. A KFF Health Tracking Poll found 12% of US adults were taking a GLP-1 in late 2025.
That share had doubled in just 18 months. Because most of these patients stay on therapy long term, plant output must keep rising each year. Any new peptide drug nearing commercial supply then competes with these contracts for the same reactors and purification lines. That competition is changing how companies plan, starting with when they book capacity.
To avoid losing slots to larger GLP-1 contracts, companies will start booking plant time during clinical trials. Early talks during mid-stage trials also give the partner time to plan equipment and staff. This lead time matters most for companies bringing their first peptide to commercial supply. Securing a slot is only half the task, though, since the route must also suit large volumes.
GLP-1 production has also proven that hybrid routes work at a commercial scale. Most peptides are still built one amino acid at a time on resin beads. That approach becomes harder to run as chains get longer and batch sizes grow. Hybrid routes ease this by building shorter pieces first, then joining them in large liquid-phase reactors. Companies with long peptides will therefore favor partners that run both methods on-site.
Small molecules will remain central because they still account for most new drugs. Their chemistry is also becoming too specialized for many developers to handle in-house.
The FDA's New Drug Therapy Approvals 2025 report lists 46 novel drugs approved that year. Of these, 34 were new molecular entities, and most of them were small molecules.
The remaining 12 approvals were biologics. So chemical synthesis still produces most newly approved drug substances. What has changed is how difficult these molecules are to make. Many carry intricate 3D structures and strict limits on impurities. Those demands shift API and peptide outsourcing toward specialists in two ways.
The first shift involves equipment, since some molecules need reactions at very low temperatures or under hydrogen pressure. Building that equipment is hard to justify for a developer with only one or two molecules.
A specialist partner, by contrast, spreads the same investment across many client projects. Its teams have often solved similar scale-up problems before, so fewer surprises reach the plant. For smaller biotech companies, this arrangement avoids heavy capital spending before clinical results arrive.
shift involves cost, because complex molecules make the manufacturing route a major cost driver. A shorter route removes processing steps and cuts solvent use along the way. Cleaner reactions then reduce the purification work needed once production reaches commercial scale. Reviewing the route before regulatory filing captures these savings and avoids costly changes after approval.
For companies planning their 2027 supply, Neuland Laboratories offers small molecule and peptide API capabilities under one roof. The CDMO operates three cGMP-certified facilities near Hyderabad, India, approved by the US FDA and EMA. Japan's PMDA has also approved these sites, extending the same quality standing to Japanese supply.
Behind this manufacturing base sit more than 400 R&D scientists. They take molecules from early route design through to commercial-scale production. Along the way, the teams have also supported 25 IND and 4 NDA filings for clients. Companies looking to secure capacity and chemistry expertise early can get in touch with the Neuland team today.
Yes, generic GLP-1 launches are likely to add more pressure on peptide capacity. Patents on a leading GLP-1 molecule expired in 2026 in several markets outside the US and Europe. Generic makers in those markets now need large volumes of peptide API. They compete with branded supply and new peptide drugs for the same plants.
Before signing a long-term supply agreement, companies should check whether the CDMO can grow with their molecule. Here are a few useful questions to ask:
● What is the capacity expansion plan for the next three to five years?
● What did recent regulatory inspections find?
● Is there a backup site if one plant goes offline?
Yes, a company can move its API to a new CDMO after approval, but it takes planning. Regulators must be told about the manufacturing site change, and some changes need approval first. The new site must also show that its material matches the original in quality. This process often takes many months.
shift involves cost, because complex molecules make the manufacturing route a major cost driver. A shorter route removes processing steps and cuts solvent use along the way. Cleaner reactions then reduce the purification work needed once production reaches commercial scale. Reviewing the route before regulatory filing captures these savings and avoids costly changes after approval.
Yes, peptides usually need extra quality tests beyond those used for small molecules. Here is what labs typically check:
● The amino acid sequence is correct.
● There are no impurities from missing or extra amino acids.
● Molecules have not formed clumps or larger particles.
A CDMO handling both types needs analytical teams trained for each.
MBTpg/ARC
